-
1 week ago | 
dealstreetasia.com | Stephanie Li
Global pharma giant Pfizer’s recent announcement of a record $1.25-billion upfront payment to buy the exclusive global license of Hong Kong-listed 3SBio’s cancer drug underscores the growing momentum displayed by big pharma towards investments in Chinese biotech assets. Register now to enjoy 3 free articles per month, or log in to continue reading.
-
1 week ago | 
dealstreetasia.com | Stephanie Li
Eieling Technology, which develops medical ultrasound solutions to detect conditions such as liver fibrosis and fatty liver, has secured “several hundred million” HKD in its latest funding round, without disclosing the investors. Founded in 2018, the Hong Kong-based firm was previously a project incubated by the Department of Biomedical Engineering of the Hong Kong Polytechnic University. Eieling aims to develop a portable ultrasound device for diagnosis and screening of liver fibrosis.
-
2 weeks ago | 
dealstreetasia.com | Stephanie Li
The Hong Kong Investment Corporation (HKIC), an investment company wholly-owned by the Hong Kong government, has announced partnerships with several general partners (GPs), including Gobi Partners, Lanchi Ventures, and Gaw Capital, as the wealth fund bolsters its position as the hub of patient capital. HKIC said the firm has jointly created a new fund named Patient Capital Strategic Fund with Gobi Partners, an Asian venture capital firm dual-headquartered in Kuala Lumpur and Hong Kong.
-
2 weeks ago | 
dealstreetasia.com | Stephanie Li
Airwallex, a global payments and financial platform for businesses, has raised $300 million in a Series F funding round, which includes $150 million worth of secondary share transfers, as the fintech giant looks on track to hit $1 billion in annualised revenue in this year amid aggressive expansion plans.
-
2 weeks ago | 
dealstreetasia.com | Stephanie Li
Chinese financial advisory firm Lighthouse Capital has launched a new fund targeting early-stage Artificial Intelligence (AI)-enabled opportunities, with a fund size of at least $50 million, according to a release on Monday. The vehicle, Lighthouse Founders’ Fund (L2F), has hit its first close, roping in limited partners (LPs), including several internet and tech entrepreneurs and family offices. Leo Zheng, founder and CEO of Lighthouse Capital, will serve as the founding partner of L2F.
-
2 weeks ago | 
dealstreetasia.com | Stephanie Li
Hong Kong-headquartered PHASE Scientific, a biotech firm engaged in early disease detection through proprietary urine-based diagnostics, has snapped $34 million in a Series A funding round led by Hong Kong-listed asset management firm Value Partners Group. “With this capital, we will accelerate R&D and commercialisation efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market,” said Ricky Chiu, founder, chairman, and CEO of PHASE Scientific.
-
2 weeks ago | 
dealstreetasia.com | Stephanie Li
The former Asia team of global private placement agent Monument Group has launched an independent private market capital solution platform, New Peak Partners, the firm’s managing partner, Niklas Amundsson, shared in a post on his LinkedIn page on Monday. The Hong Kong-headquartered firm said it will support managers in the region in raising capital from North America, Europe, and the Middle East and help international clients access Asia Pacific’s growing investor base.
-
2 weeks ago | 
dealstreetasia.com | Stephanie Li
Maison Capital, a consumer-focused private equity firm in China, has rebranded to Fong Capital Partners as the firm shifts its investment focus to innovative firms, especially in medical technology. Start your deal-making journey now!Subscribe now to enjoy unlimited access at just $59. Premium coverage on private equity, venture capital, and startups in Asia. Exclusive scoops from our reporters in nine key markets. In-depth interviews with industry leaders shaping the ecosystem.
-
3 weeks ago | 
dealstreetasia.com | Stephanie Li
Dual-currency biomedical venture firm Lily Asia Ventures (LAV) has closed its seventh USD fund, roping in sovereigns, pensions, endowments, foundations, family offices and funds of funds. Start your deal-making journey now!Subscribe now to enjoy unlimited access at just $59. Premium coverage on private equity, venture capital, and startups in Asia. Exclusive scoops from our reporters in nine key markets. In-depth interviews with industry leaders shaping the ecosystem.
-
3 weeks ago | 
dealstreetasia.com | Stephanie Li
Autonomous agents developer Qianjue Robotics has raised “several millions of yuan” in a fresh funding round led by Gobi China and Oriza Seed, according to a recent statement. The round, which saw the participation of Xiaomiao Langcheng Investment Management, will help the firm in R&D and product iteration. The Shanghai-based firm was incubated by a group of brain-inspired experts at the Center for Brain-Inspired Computing Research (CBICR) at mainland China’s Tsinghua University.
